Journal of Pharmacovigilance

Salvigenin and Eupatorin greatly improved therapeutic index of Doxorubicin in human colon cancer cell line

4^th International Conference and Exhibition on Pharmacovigilance & Clinical Trials

August 10-12, 2015 London, UK

Nazanin Namazi Sarvestani

Posters-Accepted Abstracts: J Pharmacovigilance

Abstract:

Many of dietary flavonoids have been known to possess beneficial effects in the human body due to their antioxidative and tumor growth inhibitory activities. Natural agents could be a useful strategy to reduce the dose of hazardous chemotherapy drug. In this study, SW948 and HT-29 human colon cancer cells were treated with IC50 dose of salvigenin and eupatorin for 24 h with or without doxorubicin presence. The extent of proliferation was assessed by MTT test. To determine apoptotic cells morphologically, DAPI staining done by fluorescent microscopy. Cell cycle analysis, Annexin V-FITC/PI staining and western blot analyses were measured too. It was shown in cell cycle analysis that, these cell lines which were treated with salvigenin or eupatorin with non-effective dose of doxorubicin, arrested in G1 phase were about 40 and 30% more than doxorubicin treated cells, respectively. Moreover G2 arrest was induce by flavonoids too. On the other hand, Annexin V-FITC/PI staining confirms that combination of salvigenin or eupatorin with lower dose of doxorubicin induce greater apoptosis in colon cancer cell lines compared to doxorubicin treated cells. In addition, caspase-3 and PARP expression increased significantly in these groups to confirm that flavonoids enhanced apoptotic feature of doxorubicin in colon cancer cell lines. Synergistic effect was calculated by computer software. Natural therapeutic flavonoids regimens such as salvigenin and eupatorin, were able to potentiate doxorubicin effects in lower doses, with protecting non-tumoral cells that are needed to improve treatment of colon cancer patients, because, most colon cancer patients treated with combination therapies have only temporary responses to treatment, associated with the side effects of the therapies.